Key result
A revised, shorter voltage protocol for measuring hERG inhibition by verapamil yielded an IC50 of 210.5 nM, similar to the original CiPA protocol, but increased the success rate 5-fold.
Why the study?
To independently determine hERG inhibitory properties in order to test the reproducibility of data gathered across different laboratories and the practicality of CiPA-defined recording conditions.
Does a revised, shorter voltage protocol accurately measure hERG channel inhibition by verapamil compared to the standard CiPA protocol in HEK293 cells?
Does a revised, shorter voltage protocol accurately measure hERG channel inhibition by verapamil compared to the standard CiPA protocol in HEK293 cells?
Answers are grounded in this paper and cite their sources.
A shortened voltage protocol for assessing hERG channel inhibition by drugs at physiological temperature yields similar pharmacological data to the standard CiPA protocol but with a 5-fold higher experimental success rate, improving feasibility for regulatory science.
The Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative reassesses using the inhibition of hERG channels by drugs as the major determinant for assessment of a drug’s potential to cause ‘Torsades de Pointes’ (TdP) cardiac arrhythmias. Here we report on one phase of CiPA: independent determination of hERG inhibitory properties in order to test the reproducibility of data gathered in different labs and the practicality of using the CiPA-defined recording conditions. We measured inhibition of hERG1a potassium channels stably expressed in HEK293 cells using manual whole-cell patch-clamp electrophysiology recordings at the physiological temperature of 37°C by verapamil, a known hERG inhibitor. We report that the IC50 for inhibition (180.4nM) and the Hill coefficient (1.4) for verapamil measured in an academic lab were similar to the IC50 (204nM) and Hill coefficient (0.9) measured at the Food and Drug Administration labs, indicating low variability in measurements between labs. We report that the CiPA step voltage protocol, a series of voltage steps characterized by 10 second duration depolarizing pulses at 37°C, resulted in a very low (5%) experimental success rate per cell in our hands. To circumvent the low success rate, we shortened the duration of the depolarizing pulse to 3 seconds (from 10 seconds) and shortened the duration of interpulse intervals, which is more consistent with the duration of voltage pulses used in biophysical studies of hERG, such that the entire revised protocol was shortened from over 30 minutes to approximately 10 minutes in duration. Using the revised protocol, we found an IC50 of inhibition by verapamil of 210.5 nM and Hill coefficient of 1.2. These values were similar to those generated using the original, longer CiPA step protocol. Furthermore, our success rate using the shortened protocol rose to 25%, an increase of 5-fold over the initial protocol. In summary, we captured key pharmacological data for subsequent analysis in CiPA using a revised, shorter protocol with an enhanced success rate and an overall enhanced feasibility. We propose the shorter protocol is more pragmatic for generation of hERG channel drug inhibition data for CiPA and other regulatory sciences.
No takes yet. Share an insight, caveat, or question.
Johnson et al. (2023) studied hERG channel inhibition (in vitro). Revised shorter voltage protocol vs. Original CiPA voltage protocol was evaluated on IC50 of hERG inhibition by verapamil (nM). A revised, shorter voltage protocol for measuring hERG inhibition by verapamil yielded an IC50 of 210.5 nM, similar to the original CiPA protocol, but increased the success rate 5-fold.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: